ALLMedicine™ Triple-negative Breast Cancer Center

Jul 1st, 2022 - Tumor-infiltrating lymphocytes (TILs) have shown prognostic value in breast cancer. This study evaluated the TILs scores in 186 Portuguese patients diagnosed with early breast cancer, with special focus on HER2 subtype. Stromal TILs were scored on...

Jul 1st, 2022 - To investigate the value of the combined diagnosis of multiparametric MRI-based deep learning models to differentiate triple-negative breast cancer (TNBC) from fibroadenoma magnetic resonance Breast Imaging-Reporting and Data System category 4 (BI...

Jun 29th, 2022 - Dr Ann Partridge from the Dana-Farber Cancer Institute in Boston, Massachusetts, highlights important new data in early breast cancer presented at American Society of Clinical Oncology (ASCO) 2022. Dr Partridge begins with promising results from t.

Jun 29th, 2022 - Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) and often associated with poor survival outcomes. The bac...

Jun 28th, 2022 - This study aimed to incorporate clinicopathological, sonographic, and mammographic characteristics to construct and validate a nomogram model for predicting disease-free survival (DFS) in patients with triple-negative breast cancer (TNBC). Patient...

Jun 24th, 2022 - This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).

Jun 24th, 2022 - The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin in participants with selected tumor types (ovarian cance...

Jun 24th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival (PFS) in each of the following groups: Ia. Patients with germline BRCA (gBRCA) mutation-associated breast cancer. Ib. Pati...

Jun 22nd, 2022 - The primary objective of Part A of this study is to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716 as monotherapy in advanced solid malignancies and to characterize the safety, and tolerability of GS-9716 monothera...

Jun 29th, 2022 - Dr Ann Partridge from the Dana-Farber Cancer Institute in Boston, Massachusetts, highlights important new data in early breast cancer presented at American Society of Clinical Oncology (ASCO) 2022. Dr Partridge begins with promising results from t.

Jun 23rd, 2022 - Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC). Major finding: The obj.

Jun 20th, 2022 - Although breast cancer occurs less frequently in Black women compared to White women, they have a much higher risk of dying from the disease. In the United States, age-adjusted breast cancer mortality between 2014 and 2018 was approximately 40% hi...

Jun 6th, 2022 - An antibody drug conjugate that targets a cell-surface antigen found on most breast and bladder cancers demonstrated improved progression-free survival over standard chemotherapy in patients with endocrine-resistant hormone receptor positive/HER2 ...

Jun 5th, 2022 - Results of the KEYNOTE-522 clinical trial highlight the importance of neoadjuvant treatment with pembrolizumab for improving survival in patients with early triple negative breast cancer (TNBC). The findings were presented in Chicago June 4 and 5.